endocrine:sglt2:empagliflozin []

This page is read only. You can view the source, but not change it. Ask your administrator if you think this is wrong.
====== Empagliflozin ======

Empagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor used for diabetes, heart failure, and chronic kidney disease.

It was the first SGLT2 inhibitor to demonstrate cardiovascular mortality reduction.

→ [[endocrine:sglt2:start|SGLT2 Inhibitors Overview]]

--------------------------------------------------------------------

===== Mechanism of Action =====

Location:
• Proximal convoluted tubule

Action:
• Blocks SGLT2 transporter
• Increases urinary glucose excretion
• Causes mild natriuresis
• Reduces intraglomerular pressure

Physiologic effects:

• ↓ Blood glucose
• ↓ Preload (mild diuretic effect)
• ↓ Blood pressure
• ↓ Renal hyperfiltration
• Improved cardiac efficiency

Cardiorenal benefits extend beyond glycemic control.

--------------------------------------------------------------------

===== Indications =====

==== Type 2 Diabetes Mellitus ====

• Glycemic control
• Reduces major adverse cardiovascular events
• Promotes modest weight loss

--------------------------------------------------------------------

==== Heart Failure ★ ====

Indicated for:

• HFrEF
• HFpEF

Benefits:

• ↓ HF hospitalization
• ↓ Cardiovascular mortality
• Effective with or without diabetes

Part of the Four Pillars of GDMT in HFrEF.

→ [[cardio:heart_failure:start|Heart Failure Module]]

--------------------------------------------------------------------

==== Chronic Kidney Disease ★ ====

• Slows decline in GFR
• Reduces albuminuria
• Reduces risk of kidney failure

--------------------------------------------------------------------

===== Major Trials =====

EMPA-REG OUTCOME:

• Reduced cardiovascular death
• Reduced HF hospitalization

EMPEROR-Reduced:

• Benefit in HFrEF

EMPEROR-Preserved:

• Benefit in HFpEF

--------------------------------------------------------------------

===== Adverse Effects =====

Common:

• Genital mycotic infections
• Polyuria
• Volume depletion
• Hypotension

Serious (rare):

• Euglycemic DKA
• Fournier gangrene

--------------------------------------------------------------------

===== Contraindications / Cautions =====

• Type 1 diabetes
• Severe dehydration
• Advanced renal failure (indication-dependent)

Hold during:

• Acute illness
• Major surgery
• Prolonged fasting

--------------------------------------------------------------------

===== Empagliflozin vs Dapagliflozin =====

[[endocrine:sglt2:dapagliflozin|Dapagliflozin]]:

  * • Strong HF data (DAPA-HF)
  * • Strong CKD data (DAPA-CKD)

Empagliflozin:

  * • First to show CV mortality reduction
  * • Similar HF and renal benefit

Clinically interchangeable in most HF patients.

--------------------------------------------------------------------

===== Clinical Pearls =====

✔ First SGLT2 inhibitor to reduce CV mortality  
✔ Effective in HFrEF and HFpEF  
✔ Slows CKD progression  
✔ Benefits independent of diabetes  
✔ Mild diuretic effect  
✔ Hold during acute illness  

--------------------------------------------------------------------

Related:

→ [[cardio:heart_failure:start|Heart Failure Module]]
→ [[endocrine:sglt2:start|SGLT2 Inhibitors Overview]]
→ [[cardio:intro:start|Cardiovascular Modules]]